GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DRI Healthcare Trust (TSX:DHT.U) » Definitions » Financial Strength

DRI Healthcare Trust (TSX:DHT.U) Financial Strength : 4 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DRI Healthcare Trust Financial Strength?

DRI Healthcare Trust has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate DRI Healthcare Trust's interest coverage with the available data. DRI Healthcare Trust's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.64. Altman Z-Score does not apply to banks and insurance companies.


DRI Healthcare Trust Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

DRI Healthcare Trust's Interest Expense for the months ended in Dec. 2023 was $-6.3 Mil. Its Operating Income for the months ended in Dec. 2023 was $0.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $145.5 Mil.

DRI Healthcare Trust's Interest Coverage for the quarter that ended in Dec. 2023 is

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

DRI Healthcare Trust's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 145.478) / 227.456
=0.64

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Altman Z-Score does not apply to banks and insurance companies.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DRI Healthcare Trust  (TSX:DHT.U) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

DRI Healthcare Trust has the Financial Strength Rank of 4.


DRI Healthcare Trust Financial Strength Related Terms

Thank you for viewing the detailed overview of DRI Healthcare Trust's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


DRI Healthcare Trust (TSX:DHT.U) Business Description

Traded in Other Exchanges
Address
100 King Street West, 1 First Canadian Place, Suite 7250, Toronto, ON, CAN, M5X 1B1
DRI Healthcare Trust is a pioneer in global pharmaceutical royalty monetization with a more than 30-year history of accelerating innovation by providing capital to inventors, academic institutions, and biopharma companies. In return for providing capital to biopharmaceutical innovators, the company is building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world.